BMJ 2013;347:f5032 doi: 10.1136/bmj.f5032 (Published 14 August 2013)





AVASTIN IN MACULAR DEGENERATION

Bevacizumab must be specially prepared for intraocular use

Ilias Georgalas *assistant professor, ophthalmic surgeon*, Dimitris Papaconstantinou *assistant professor*, Theodore Paraskevopoulos *ophthalmic surgeon*, Chryssanthi Koutsandrea *associate professor*

Department of Ophthalmology, University of Athens, Athens, Greece

Torjesen clearly sums up the results of a recent trial showing that off-label use of bevacizumab (Avastin) is as effective as the more expensive licensed treatment for wet age related macular degeneration—ranibizumab (Lucentis). ¹² This will provide an effective treatment for people who cannot afford the more expensive drug.

However, the article did not mention that special techniques and precautions are needed when dividing and preserving bevacizumab for intraocular use. There are many ways to do this, and ophthalmologists should be aware that simply withdrawing bevacizumab from the vial and injecting it into the eye may not be safe.

In the IVAN 2 study, the pharmacy followed strict standard operating procedures and guidelines for preparing bevacizumab for intraocular use that were submitted to and approved by the UK Medicines and Healthcare Products Regulatory Agency.

This information is important because misconceptions about the use or misuse of bevacizumab could lead to serious complications, such as endophthalmitis, and could permanently affect patients' vision. Such problems could also discourage ophthalmologists from using bevacizumab and also prevent authorities from approving the off-label use of this useful drug.

Competing interests: None declared.

- 1 Torjesen I. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds. BMJ 2013;347:f4678. (23 July.)
- 2 Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. *Lancet* 2013; published online 18 Jul. doi:10.1016/S0140-6736(13)61501-9.

Cite this as: *BMJ* 2013;347:f5032

© BMJ Publishing Group Ltd 2013